The ATAD3A Knockout MCF-7 Polyclonal Cells provide a genetically modified cell population generated by CRISPR/Cas9-mediated disruption of the human ATAD3A gene in the MCF-7 host background. This product delivers a heterogeneous polyclonal knockout cell pool, enabling robust loss-of-function studies without clonal isolation artefacts. The polyclonal format preserves population-level diversity while ensuring targeted disruption of ATAD3A, allowing researchers to examine gene function in a context that reflects native cell?to?cell variability. This model is ideally suited for investigating mitochondrial biology, apoptosis regulation, and hormone?signaling crosstalk in a breast cancer setting.
The MCF-7 host cell line is an estrogen receptor?positive (ER+), progesterone receptor?positive (PR+), and HER2?negative human mammary epithelial adenocarcinoma. Established from the malignant pleural effusion of a 69?year?old female with metastatic breast adenocarcinoma, MCF-7 cells are a widely accepted model for estrogen?responsive breast cancer. They retain key hormonal responses and are extensively employed to dissect endocrine therapy mechanisms, metabolic reprogramming, and chemosensitivity. This well?characterized background provides a clinically relevant platform for evaluating the impact of ATAD3A ablation on breast cancer pathophysiology.
ATAD3A encodes an inner mitochondrial membrane ATPase that orchestrates critical mitochondrial processes. It directly interacts with ATAD3B, MICOS complex subunits (MIC60 and MIC19), and mtDNA nucleoid proteins such as TFAM, positioning it as a central hub for mitochondrial architecture, cholesterol trafficking, and mtDNA maintenance. ATAD3A facilitates cholesterol transfer from the outer to the inner membrane via interactions with VDAC and StAR, supporting steroidogenic acute regulatory protein?mediated steroidogenesis. It also regulates mtDNA replication through TFAM, while controlling apoptosis by influencing BAX/BAK activation. Upstream, ATAD3A responds to NR5A1/SF?1 transcriptional control, mitochondrial import stress, and endoplasmic reticulum stress, placing it at the intersection of metabolic and stress?responsive pathways.
In the estrogen?sensitive MCF-7 breast cancer model, ATAD3A knockout perturbs mitochondrial cholesterol flux and hormone synthesis, potentially altering estrogen?driven proliferation. Loss of ATAD3A also destabilizes mtDNA organization and sensitizes cells to intrinsic apoptosis via BAX/BAK effectors, making this model highly relevant for studying chemoresistance and mitochondrial?targeted therapies. The polyclonal knockout population captures heterogeneous responses that may mimic tumor heterogeneity, providing a powerful tool for dissecting how mitochondrial dysfunction impacts breast cancer cell fate, metabolism, and treatment sensitivity.
This knockout model is suitable for diverse investigative workflows. Researchers can assess ATAD3A protein levels and apoptosis markers by Western blotting, quantify mtDNA copy number via RT?qPCR, measure cholesterol accumulation, visualize mitochondrial morphology with immunofluorescence, and evaluate chemotherapeutic sensitivity through cell viability assays. Additional functional readouts include Seahorse metabolic profiling and co?immunoprecipitation of ATAD3A interactors like MIC60 or TFAM. These applications empower studies in chemoresistance mechanisms, mitochondrial biology, breast cancer metabolism, drug screening, and hormone signaling crosstalk. For further information or technical support, please contact Ascent Research.
